6 Million Women Want Hot Flash Treatment. 28,700 Got A Prescription

A new antibody readout, a 24-day half-life, and what the migraine biologics already learned about treating a condition where the alternative is no treatment at all

AbCellera randomized 92 postmenopausal women, each averaging roughly ten moderate or severe hot flashes a day, to a single subcutaneous 600 milligram dose of ABCL635 or to placebo, 46 in each arm, and measured them across four weeks.

At week four, the treated group recorded 8.8 fewer moderate or severe events per day than at baseline, against 3.5 for placebo.

A placebo-adjusted difference of 5.3, p<0.001. In percentage terms, 83% against 33%. Severity fell 1.4 points against 0.3. Significance held from week one through week four.

Whether this class of drug reduces hot flashes is close to answered. Whether it reaches the women who have them is not.

The company reported improvements in sleep and in patient global impression of change, no serious adverse events, no severe adverse events, and no discontinuations. Headache, fatigue and injection site reaction were the most common adverse events.

Those figures are AbCellera's own, released yesterday, August 10, 2026, from the Phase 2 portion of a Phase 1/2 trial registered as NCT07118891.

They are top-line and not peer reviewed. Forty-six women per arm across four weeks is small and short, and the placebo arm's 33% reduction is a strong response in a group that size.

AbCellera described the result as potentially best in class. Cross-trial comparison in this category has a documented reliability problem. Writing in Maturitas, researchers took patient-level data from the fezolinetant SKYLIGHT 1 and 2 trials and matched it to the populations and designs of the elinzanetant OASIS 1 and 2 trials. Before and after matching, they found no statistically significant difference in vasomotor symptom frequency at weeks one, four or twelve. Two approved drugs that read as distinct on separate trial reports converged once the populations were aligned.

The company described a different bar for itself in May. On AbCellera's first quarter earnings call, founder and chief executive Carl Hansen laid out the base commercial profile the program was building toward. Efficacy comparable to small molecules, a cleaner safety profile without liver monitoring, and once-monthly subcutaneous dosing.

Parity on efficacy. The advantage was going to come from everywhere else.

In May 2024, an estimated 28,700 patients were dispensed Veozah from United States outpatient retail pharmacies. The figure comes from the FDA, disclosed inside a drug safety communication. AbCellera estimates the United States population with moderate to severe vasomotor symptoms at approximately 12 million women, more than six million of whom seek treatment.

Vasomotor symptoms affect up to 80% of women passing through menopause and persist for an average of seven to nine years, longer than ten years in about a third of cases. A Bayesian network meta-analysis published in Menopause in January 2024 found no significant difference in symptom frequency between fezolinetant 45 mg and any of the 27 hormone therapy regimens it evaluated. Its lead author, Antonia Morga, is employed by Astellas, the drug's manufacturer.

Medicine that performs like the standard of care, for a condition affecting most women for the better part of a decade, reaching a fraction of 1% of those looking for it.

Astellas named part of the reason itself. In February 2024 the company revised its Veozah fiscal-year projection to 7.1 billion yen, roughly $50 million, and said it was reviewing a peak estimate previously set between 300 and 500 billion yen. Chief financial officer Atsushi Kitamura told analysts on the company's quarterly call that direct-to-consumer marketing had underperformed, then pointed at prescribing behavior. "Based on market research, more healthcare providers than we assumed have a perception that the current coverage progress is not enough to actively prescribe Veozah, which is impacting the uptake."

Then the label moved. On September 12, 2024 the FDA warned that fezolinetant could cause rare but serious liver injury, following a postmarketing report of a patient with elevated liver values and symptoms within approximately 40 days of starting treatment. On December 16 it added a Boxed Warning and raised monitoring to monthly liver blood tests for the first two months, on top of tests already required at months three, six and nine.

The list price is $583.50 for 30 tablets as of January 2026, roughly $7,000 a year annualized straight from that figure. Generic off-label options including venlafaxine and gabapentin run $10 to $30 a month.

The boxed warning, the lab schedule, the prior authorization and the copay all sit on the treated path. The untreated path carries none of them.

ABCL635 targets NK3R on KNDy neurons in the infundibular nucleus of the hypothalamus, the receptor two approved drugs already act on. What differs is the molecule and the schedule. In Phase 1, AbCellera reported linear, dose-proportional pharmacokinetics and an estimated half-life of approximately 24 days. That profile is what supports a once-monthly injection.

It also means the drug cannot be taken back.

When fezolinetant's liver signal appeared, the FDA's remedy was to stop the drug, and in the reported case the patient's values returned to normal after discontinuation. A tablet clears within about a day of the last dose. A molecule with a 24-day half-life takes four to five half-lives to leave the body, which is months.

AbCellera reported no liver enzyme elevations at any dose in Phase 1, and nothing in the Phase 2 safety data contradicts that. But a single-dose study cannot describe what happens on the second dose. Repeat-dose immunogenicity, the standard failure mode for chronic biologics, is unmeasurable in a trial where nobody received one.

AbCellera is following Phase 2 participants an additional eight weeks to build the pharmacokinetic and pharmacodynamic model it will take to regulators. That twelve-week dataset, not the four-week efficacy number, defines the dosing interval and therefore the product. The company has said its goal is a subcutaneous auto-injector pen.

Migraine ran this experiment already.

In May 2018, erenumab became the first biologic approved for migraine prevention. A once-monthly subcutaneous antibody at $6,900 a year, for a nonfatal condition that affects nearly 50 million Americans concentrated between 25 and 55, skews heavily female, and competes against generic oral preventives costing a fraction as much. Fezolinetant's annualized list price today is roughly the same.

The gate went up immediately. UnitedHealthcare's prior authorization program for the class carries an initial approval date of June 2018, one month after erenumab cleared the FDA. Global sales moved from $119 million in 2018 to $542 million in 2020. Manufacturers bought their way through with free drug, two months at launch for erenumab and twelve months for the third entrant to market.

The gate has not come down. UnitedHealthcare's current criteria, effective July 1 of this year, still require documented failure across two separate older prophylactics, each after a trial of at least two months, before approving one of the injectable antibodies. The qualifying list is beta-blockers, candesartan, divalproex, Botox, an SNRI, topiramate, and tricyclics.

The same policy document cites, in its own reference list, the American Headache Society's 2024 position statement declaring CGRP-targeting therapies a first-line option for migraine prevention.

First-line by the guideline. Third-line by the coverage criteria.

Policy is what moves that. The same UnitedHealthcare document waives the non-CGRP trial requirement entirely for California business, and shortens the required trial to 30 days in Connecticut, Kentucky and Mississippi. Where a state legislated, the step therapy disappeared.

The friction did not disappear. It moved.

The migraine antibodies are self-injected pens. They still route through specialty pharmacy, and they still sit behind two failed generics.

Fezolinetant's burden was monitoring, a boxed warning, and a coverage picture its own maker called insufficient in prescribers' eyes. A monthly biologic inherits a different one: prior authorization, step therapy through cheaper orals, and specialty pharmacy routing. Whether that trade is better for a woman with hot flashes is an empirical question, and it is a different question from the one Phase 3 will answer.

AbCellera has said it will move at maximum speed toward registrational trials in menopausal VMS and does not expect to reinvent Phase 3 design given the precedent set by approved therapies. Executives have pointed to 2027 as the year of execution. Nothing about that timeline touches the coverage question.

Three drugs now reduce hot flash frequency, one of them at parity with hormone therapy. By AbCellera's own estimate, more than six million American women are looking for treatment. A federal count put 28,700 of them on a prescription in May 2024.

Nothing in that gap is a molecule problem. The trials that will define this category still measure molecules.

The evidence points at distribution. The pipeline still points at chemistry.

This is market and evidence analysis, not medical advice. Whether any therapy is appropriate for an individual is a clinical decision.